Skip to main content
SpringerLink
Log in
Book cover

Neuro-Psychopharmaka pp 113–130Cite as

MAO-B-Hemmer

  • Chapter

  • 42 Accesses

Zusammenfassung

MAO-B-Hemmer inhibieren per definitionem die Aktivität des Enzyms Monoaminoxidase (MAO) Typ B durch Konkurrenz mit dem spezifischen Substrat. Entsprechend der Reversibilität der Hemmung unterscheidet man:

  1. 1.

    kompetitive, reversible und

  2. 2.

    irreversible Inhibitoren.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Benakis (1985) Pharmacokinetic and metabolic data of Jumex® in human volunteers. In: Marton J, Zak F, Szebeni R (eds) Proceedings of the International Symposium on (-)-Deprenyl, Jumex®. Chinoin Pharmaceutical and Chemical Works, Budapest, pp 33–37

    Google Scholar 

  • Bieck PR (1989) Hypertensive Krisen unter reversiblen Hemmstoffen der Monoaminoxidase? Ergebnisse von Tyramin-Interaktionsstudien. In: Laux G, Riederer P (Hrsg) Neue selektive Monoaminoxidase-Hemmer in der Therapie depressiver Erkrankungen. Psychiatr Prax 16: 25–31

    Google Scholar 

  • Birkmayer WP, Riederer P, Linauer W, Knoll J (1984) L-Deprenyl plus L-phenylalanine in the treatment of depression. J Neural Transm 59: 81–87

    Article  PubMed  CAS  Google Scholar 

  • Birkmayer W, Knoll J, Riederer P, Youdim MBH, Hars V, Marton J (1985) Increased life expectancy resulting from addition of L-deprenyl to Madopar® treatment in Parkinson’s disease: a longterm study. J Neural Transm 64: 113–127

    Article  PubMed  CAS  Google Scholar 

  • Biackwell B, Marley E (1966) Interactions of cheese and of its constituents and monoamine oxidase inhibitors. Br J Pharmacol 26: 120–141

    Google Scholar 

  • Cohen G (1986) Monoamine oxidase, hydrogen peroxide, and Parkinson’s disease. In: Yahr MD, Bergmann KJ (eds) Advances in neurology, vol 45 . Raven Press, New York, pp 119–125

    Google Scholar 

  • Cohen G, Psik P, Cohen B, Leist A, Mythilineou C, Yahr MD (1984) Pargyline and deprenyl prevent the neurotoxicity of 1-methyl-4-phenyl1,2,3–6-tetrahydropyridine (MPTP) in monkeys. Eur J Pharmacol 106: 209–210

    Article  PubMed  CAS  Google Scholar 

  • Danielczyk W, Streifler M, Konradi C, Riederer P, Moll G (1989) Platelet MAO-B activity and the psychopathology of Parkinson’ disease, senile dementia and multi-infarct dementia. Acta Psychiatr Scand 78: 730–736

    Article  Google Scholar 

  • Da Prada M, Kettler R, Zurcher G, Keller HH (1988) Hemmer der MAO-B und COMT: Möglichkeiten ihrer Anwendung bei der Parkinson-Therapie aus heutiger Sicht. In: Fischer PA (Hrsg) Modifizierende Faktoren bei der ParkinsonTherapie. Editiones Roche, Basel, S 309–323

    Google Scholar 

  • Eisler T, Teravainen H, Nelson R et al. (1981) Deprenyl in Parkinson’s disease. Neurology 31: 19–23

    Article  PubMed  CAS  Google Scholar 

  • Ekstedt B, Magyar K, Knoll J (1979) Does the B form selective monoamine oxidase inhibitor lose selectivity by long term treatment? Biochem Pharmacol 28: 919–923

    Article  PubMed  CAS  Google Scholar 

  • Elsworth JD, Glover V, Reynolds GP et al. (1978) Deprenyl administration in man: selective monoamine oxidase B inhibitor without the “cheese effect”. Psychopharmacology 57: 33–38

    Article  PubMed  CAS  Google Scholar 

  • Finberg J PM, Tenne M (1982) Relationship between tyramine potentiation and selective inhibition of monoamine oxidase types A and B in the rat vas deferens. Br J Pharmacol 77: 13–21

    Article  PubMed  CAS  Google Scholar 

  • Fowler JS, Mcgregor RR, Wolf AP et al. (1987) Mapping human brain monoamine oxidase A and B with 11C-labeled suicide inactivators and PET. Science 235: 481–485

    Article  PubMed  CAS  Google Scholar 

  • Golbe LI (1988) Deprenyl as symptomatic therapy in Parkinson’s disease. Clin Neuropharmacol 11: 387–400

    Article  PubMed  CAS  Google Scholar 

  • Heikkila RL, Manzino L, Cabbat FS, Duvoisin RC (1984) Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by monoamine oxidase inhibitors. Nature 311: 467–469

    Article  PubMed  CAS  Google Scholar 

  • Johnston P (1968) Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem Pharmacol 17: 1285–1297

    Article  PubMed  CAS  Google Scholar 

  • Kalir A, Sabbagh A, Youdim MBH (1981) Selective acetylenic ‘suicide’ and reversible inhibitors of monoamine oxidase types A and B. Br J Pharmacol 73: 55–64

    Article  PubMed  CAS  Google Scholar 

  • Karoum F, Chuang LW, Eisler T, Calne DB, Leibowitz MR, Quitkin FM, Klein DF, Wyatt RJ (1982) Metabolism of (-)-deprenyl to amphetamine and methamphetamine may be responsible for deprenyl’s therapeutic benefit: a biochemical assessment. Neurology 32: 503–509

    Article  PubMed  CAS  Google Scholar 

  • Keller HH, Kettler R, Keller G, Da Prada M (1987) Short-acting novel MAO inhibitors: in vitro evidence for the reversibility of MAO inhibition by moclobemide and Ro 16–6491. Naunyn-Schmiedebergs Arch Pharmacol 335: 15–20

    Google Scholar 

  • Knoll J (1976) Analysis of the pharmacological effects of selective monoamine oxidase inhibitors. In: Wolstenholme GEW, Knight J (eds) Monoamine oxidase and its inhibition. Elsevier/North-Holland, Amsterdam, pp 131–161 (Ciba Foundation Symposium 39)

    Google Scholar 

  • Knoll J (1978) The possible mechanism of action of (-)deprenyl in Parkinson’s disease. J Neural Transm 43: 177–198

    Article  PubMed  CAS  Google Scholar 

  • Knoll J (1983) Deprenyl (selegiline): the history of its development and pharmacological action. Acta Neurol Scand [Suppl] 95: 57–80

    Article  CAS  Google Scholar 

  • Knoll J (1986a) The pharmacology of (-)-deprenyl. J Neural Transm [Suppl] 22: 75–89

    CAS  Google Scholar 

  • Knoll J (1986b) Role of B-type monoamine oxidase inhibition in the treatment of Parkinson’s disease. In: Shah NS, Donald HG (eds) Movement disorders. Plenum Press, New York, pp 53–81

    Chapter  Google Scholar 

  • Knoll J (1987) R-(-)-Deprenyl (Selegiline, Movergan®) facilitates the activity of the nigrostriatal dopaminergic neuron. J Neural Transm [Suppl] 25: 45–69

    CAS  Google Scholar 

  • Knoll J, Magyar K (1972) Some puzzling effects of monoamine oxidase inhibitors. Adv Biochem Psychopharmacol 5: 393–408

    PubMed  CAS  Google Scholar 

  • Konradi C, Riederer P, Heinsen H (1989) Histochemistry of MAO subtypes in the brainstem of humans: a relation to the radical hypothesis of Parkinson’s disease? In: Przuntek H, Riederer P (eds) Early diagnosis and preventive therapy in Parkinson’s disease. Springer, Wien New York, pp 243–249

    Chapter  Google Scholar 

  • Kopin IJ (1986) Toxins and Parkinson’s disease MPTP parkinsonism in humans and animals. In: Yahr MD, Bergmann KJ (eds) Advances in neurology, vol 45. Raven Press, New York, pp 137–144

    Google Scholar 

  • Lee DH, Mendoza M, Dvorozniak MT, Chung E, Van Woert MH, Yahr MD (1989) Platelet monoamine oxidase in Parkinson patients: effect of L-deprenyl therapy. J Neural Transm [P-DSect] 1: 189–194

    Article  CAS  Google Scholar 

  • Mendlewicz J, Youdim MBH (1983) L-Deprenyl, a selective monoamine oxidase type B inhibitor in the treatment of depression: a double blind evaluation. Br J Psychiatry 142: 507–511

    Article  Google Scholar 

  • Oreland L, Johansson F, Ekstedt J (1983) Dose regimen of deprenyl (selegiline) and platelet MAO activities. Acta Neurol Scand [Suppl] 95: 87–89

    Article  CAS  Google Scholar 

  • Reynolds GP, Elsworth JD, Blau K, Sandler M, Lees AJ, Stern GM (1978) Deprenyl is metabolized to methamphetamine and amphetamine in man. Br J Clin Pharmacol 6: 542–544

    Article  PubMed  CAS  Google Scholar 

  • Riederer P, Youdim MBH (1986) Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with L-deprenyl. J Neurochem 46: 1359–1365

    Article  PubMed  CAS  Google Scholar 

  • Riederer P, Przuntek H (1988) Morbus Parkinson — Selegilin (R-(-)-Deprenyl, Movergan®). Ein neues Therapiekonzept. Springer, Wien New York

    Google Scholar 

  • Riederer P, Youdim MBH, Rausch WD, Birkmayer W, Jellinger K, Seemann D (1978) On the mode of action of L-deprenyl in the human central nervous system. J Neural Transm 43: 217–226

    Article  PubMed  CAS  Google Scholar 

  • Riederer P, Jellinger K, Seemann D (1984) Monoamine oxidase and parkinsonism. In: Tipton K, Dostert P, Strolin-Benedetti M (eds) Monoamine oxidase and disease. Academic Press, London Orlando San Diego, pp 404 415

    Google Scholar 

  • Riederer P, Konradi C, Hebenstreit G (1989) Neurochemische Perspektiven zur Funktion der Monoaminoxidase. Psychiatr Prax 16 [Suppl]: 7–11

    PubMed  Google Scholar 

  • Squires R (1972) Multiple forms of monoamine oxidase in intact mitochondria as characterized by selective inhibitors and thermal stability: a comparison of eight mammalian species. Adv Biochem Psychopharmacol 5: 355–370

    PubMed  CAS  Google Scholar 

  • Stern Y (1990) MPTP-induced parkinsonism. Prog Neurobiol 34: 107–114

    Article  PubMed  CAS  Google Scholar 

  • Stern GM, Lees AJ, Hardie RJ, Sandler M (1983) Clinical and pharmacological problems of deprenyl (selegiline) treatment in Parkinson’s disease. Acta Neurol Scand [Suppl] 95: 113–116

    Article  CAS  Google Scholar 

  • Tetrud J, Langston W (1989) The effect of deprenyl (Selegiline) on the natural history of Parkinson’s disease. Science 245: 519–522

    Article  PubMed  CAS  Google Scholar 

  • Tipton KF, Mantle TJ (1981) Inhibition of rat liver monoamine oxidase by clorgyline and deprenyl. In: Youdim MBH, Paykel ES (eds) Monoamine oxidase inhibitors: the state of the art. Wiley, Chichester, pp 3–27

    Google Scholar 

  • Youdim MBH, Finberg JPM (1986) MAO Type B inhibitors as adjunct to L-DOPA therapy. In: Yahr MD, Bergmann KJ (eds) Advances in neurology, vol 45. Raven Press, New York, pp 127–136

    Google Scholar 

  • Youdim MBH, Finberg JPM, Tipton KF (1988) Monoamine oxidase. In: Trendelenburg U, Weiner N (eds) Catecholamines I. Springer, Berlin Heidelberg New York Tokyo, pp 119–192 (Handbook of experimental pharmacology, vol 90/

    Chapter  Google Scholar 

  • Zreika M, Fozard JR, Dudley MW, Bey PH, McDonald IA, Palfreyman MG (1989) MDL 72,974: a potent and selective enzyme-activated irreversible inhibitor of monoamine oxidase type B with potential for use in Parkinson’s disease. J Neural Transm [PP-D-Sect] 1: 243–254

    Article  CAS  Google Scholar 

  • Zsiula G, Foldi P, Held G, Szekeix AM, Knoll J (1986) The effect of repeated doses of (-)deprenyl on the dynamics of monoaminergic transmission. Comparison with clorgyline. Pol Pharmacol Pharm 38: 57–67

    Article  Google Scholar 

  • Birkmayer W, Rederer P, Youdim MBH, Linauer W (1975) The potentiation of the anti-akinetic effect after L-dopa treatment by an inhibitor of MAO-B deprenyl. J Neural Transm 36: 303–326

    Article  PubMed  CAS  Google Scholar 

  • Birkmayer W, Knoll J, Riederer P, Youdim MBH, Hars V, Marton J (1985) Increased life expectancy resulting from addition of L-deprenyl to madopar treatment in Parkinson’s disease: a longterm study. J Neural Transm 64: 113–127

    Article  PubMed  CAS  Google Scholar 

  • Csanda E, Tarczy M (1987) Selegeline in the early and late phases of Parkinson’s disease. J Neural Transm [Suppl 25]: 105–113

    Google Scholar 

  • Eisler T, Terävainen H, Nelson R, Krebs H, Weise V, Lake CR, Ebert MH, Whetzel N, Murphy DL, Kopin IJ, Calne DB (1981) Deprenyl in Parkinson’s disease. Neurology 31: 19–23

    Article  PubMed  CAS  Google Scholar 

  • Fischer PA, Baas H (1987) Therapeutic efficacy of deprenyl as adjuvant therapy in advanced parkinsonism. J Neural Transm [Suppl 25]: 137–147

    Google Scholar 

  • Golbe LI, Duvoisin RC (1987) Deprenyl for on-off Parkinson’s disease. J Neural Transm [Suppl 25]: 123–129

    Google Scholar 

  • Goldstein L (1980) The “on-off’ phenomena in Parkinson’s disease. Treatment and theoretical considerations. Mt Sinai J Med 47: 80–84

    PubMed  CAS  Google Scholar 

  • Heikkila RL, Manzino L, Duvoisin RC, Cabbat FS (1984) Protection against the dopaminergic neurotoxicity of 1-methyl-4phenyl-1,2,3,6-tetrahydropyridine by monoamine oxidase inhibitors. Nature 311: 467–469

    Article  PubMed  CAS  Google Scholar 

  • Johnston JP (1968) Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem Pharmacol 17: 1285–1297

    Article  PubMed  CAS  Google Scholar 

  • Knoll J, Magyar K (1972) Some puzzling effect of monoamine oxidase inhibitors. Adv Biochem Psychopharmacol 5: 393–408

    PubMed  CAS  Google Scholar 

  • Knoll J, Vizi ES, Somogyi G (1967) Phenyliso propylmethylpropinyl-amine (E-250) tyraminantagonista hatása MTA V. Oszt Közl 18: 33–37

    Google Scholar 

  • Laux G (1992) Do MAO-B inhibitors have any role in the treatment of depression? In: Szelenyi I (ed) Inhibitors of monoamine oxidase B. Basic and clinical aspects. Birkhäuser, Basel (in press)

    Google Scholar 

  • Lees AJ, Shaw KM, Kohout, Stern GM, Elsworth JD, Sandler M, Youdim MBH (1977) Deprenyl in Parkinson’s disease. Lancet ii: 791–796

    Article  Google Scholar 

  • Mann G, Gershon S (1980) L-deprenyl, a selectice monoamine oxidase type-B inhibitor in endogenous depression. Life Sci 29: 877–882

    Article  Google Scholar 

  • Mylilä W, Sotaniemi KA, Tuominenj, Heinonen EH (1989) Selegiline as primary treatment in early phase Parkinson’s disease — an interim report. Acta Neurol Scand [Suppl 126]: 177–182

    Google Scholar 

  • Parkinson Study Group (1989a) Datatop: a multicenter controlled clinical trial in early Parkinson’s disease. Arch Neurol 46: 1052–1060

    Article  Google Scholar 

  • Parkinson Study Group (1989b) Effect of deprenyl on the progression of disability in early parkinson’s disease. N Engl J Med 321: 1364–1371

    Article  Google Scholar 

  • Presthus J, Hajba A (1983) Deprenyl (selegiline) combined with levodopa and a decarboxylase inhibitor in the treatment of Parkinson’s disease. Acta Neurol Scand 68 [Suppl 95]: 127–133

    Article  Google Scholar 

  • Przuntek H, Kuhn W (1987) The effect of R-(-)deprenyl in de novo Parkinson patients on combination therapy with levodopa and decarboxylase inhibitor. J Neural Transm [Suppl 25]: 97–104

    Google Scholar 

  • Reynolds GP, Riederer P, Sandler M, Jellinger K, Seemann D (1978) Amphetamine and 2-phenylethylamine in post-mortem parkinsonian brain after deprenyl administration. J Neural Transm 43: 271–277

    Article  PubMed  CAS  Google Scholar 

  • Rinne UK (1987) R(-)-deprenyl as an adjuvant to levodopa in the treatment of Parkinson’s disease. J Neural Transm [Suppl 25]: 149–155

    Google Scholar 

  • Stern GM, Lees AJ, Sandler M (1978) Recent observations on the clinical pharmacology of deprenyl. J Neural Transm 43: 245–251

    Article  PubMed  CAS  Google Scholar 

  • Sunderiand T, Mueller EA, Cohen RM, Jimerson DC, Pickar D, Murphy DL (1985) Tyramine pressor sensitivity changes during deprenyl treatment. Psychopharmacology 86: 432–437

    Article  Google Scholar 

  • Tetrud JW, Langston JW (1989) The effect of deprenyl (selegiline) on the natural history of Parkinson’s disease. Science 245: 519–522

    Article  PubMed  CAS  Google Scholar 

  • Ulm G, Fornadi F (1987) R-(-)-deprenyl in the treatment of end-of-dose akinesia. J Neural Transm [Suppl 25]: 163–172

    Google Scholar 

  • Yahr MD (1989) Selegiline in the treatment of Parkinson’s disease long-term experience. Acta Neurol Scand [Suppl 126]: 157–161

    Google Scholar 

  • Zornberg GL, Bodkin JA, Cohen BM (1991) Severe adverse interaction between pethidine and selegiline. Lancet 337: 246

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. M. Gerlach
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P. Riederer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. P.-A. Fischer
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Psychiatrische Universitätsklinik, Würzburg, Bundesrepublik Deutschland

    Peter Riederer

  2. Psychiatrische Universitätsklinik, Bonn, Bundesrepublik Deutschland

    Gerd Laux

  3. Psychiatrische Universitätsklinik, Basel, Schweiz

    Walter Pöldinger

Rights and permissions

Reprints and permissions

Copyright information

© 1992 Springer-Verlag Wien

About this chapter

Cite this chapter

Gerlach, M., Riederer, P., Fischer, PA. (1992). MAO-B-Hemmer. In: Riederer, P., Laux, G., Pöldinger, W. (eds) Neuro-Psychopharmaka. Springer, Vienna. https://doi.org/10.1007/978-3-7091-3330-9_6

Download citation

  • DOI: https://doi.org/10.1007/978-3-7091-3330-9_6

  • Publisher Name: Springer, Vienna

  • Print ISBN: 978-3-7091-3331-6

  • Online ISBN: 978-3-7091-3330-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation